These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

900 related items for PubMed ID: 18077495

  • 1. Cold stimulus fingertip lacticemy test--an effective method to monitor acute therapeutic intervention on primary Raynaud's phenomenon and systemic sclerosis.
    Fontenelle SM, Kayser C, Pucinelli ML, Andrade LE.
    Rheumatology (Oxford); 2008 Jan; 47(1):80-3. PubMed ID: 18077495
    [Abstract] [Full Text] [Related]

  • 2. Determination of fingertip lacticemy before and after cold stimulus in patients with primary Raynaud's phenomenon and systemic sclerosis.
    Pucinelli ML, Fontenelle S, Andrade LE.
    J Rheumatol; 2002 Jul; 29(7):1401-3. PubMed ID: 12136896
    [Abstract] [Full Text] [Related]

  • 3. Cold stimulus-fingertip lacticemy: standardization of the test in normal volunteers and diagnostic application for systemic sclerosis.
    Kayser C, Pucinelli ML, Fontenelle SM, Andrade LE.
    Microvasc Res; 2005 Jul; 70(1-2):84-9. PubMed ID: 15927207
    [Abstract] [Full Text] [Related]

  • 4. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
    Dziadzio M, Denton CP, Smith R, Howell K, Blann A, Bowers E, Black CM.
    Arthritis Rheum; 1999 Dec; 42(12):2646-55. PubMed ID: 10616013
    [Abstract] [Full Text] [Related]

  • 5. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A, Abou-Raya S, Helmii M.
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [Abstract] [Full Text] [Related]

  • 6. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM, Korn JH, Csuka ME, Medsger TA, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR.
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [Abstract] [Full Text] [Related]

  • 7. Digital vascular responses to cooling in subjects with cold sensitivity, primary Raynaud's phenomenon, or scleroderma spectrum disorders.
    Maricq HR, Weinrich MC, Valter I, Palesch YY, Maricq JG.
    J Rheumatol; 1996 Dec; 23(12):2068-78. PubMed ID: 8970043
    [Abstract] [Full Text] [Related]

  • 8. Increased urinary F2-isoprostanes in systemic sclerosis, but not in primary Raynaud's phenomenon: effect of cold exposure.
    Cracowski JL, Carpentier PH, Imbert B, Cachot S, Stanke-Labesque F, Bessard J, Bessard G.
    Arthritis Rheum; 2002 May; 46(5):1319-23. PubMed ID: 12115239
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M, Pozzi MR, Bernareggi M, Montani N, Allevi E, Catena L, Cugno M, Bottasso B, Stabilini R.
    J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis.
    Schiopu E, Hsu VM, Impens AJ, Rothman JA, McCloskey DA, Wilson JE, Phillips K, Seibold JR.
    J Rheumatol; 2009 Oct; 36(10):2264-8. PubMed ID: 19755613
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE, Shea B, Welch V, Fenlon D, Pope JE.
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [Abstract] [Full Text] [Related]

  • 17. Assessment of abnormal blood flow and efficacy of treatment in patients with systemic sclerosis using a newly developed microwireless laser Doppler flowmeter and arm-raising test.
    Kido M, Takeuchi S, Hayashida S, Urabe K, Sawada R, Furue M.
    Br J Dermatol; 2007 Oct; 157(4):690-7. PubMed ID: 17640308
    [Abstract] [Full Text] [Related]

  • 18. The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon.
    Anderson ME, Moore TL, Lunt M, Herrick AL.
    Rheumatology (Oxford); 2007 Mar; 46(3):533-8. PubMed ID: 17018538
    [Abstract] [Full Text] [Related]

  • 19. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP.
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.